Merck would like to inform you that WELIREG, in combination with KEYTRUDA or KEYTRUDA QLEX, is indicated for the adjuvant treatment of adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
NCCN has introduced a Payer Relations Resource Page, which provides information on the intended use of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
NCCN introduces a New Payer Resource Read More »
Astrazeneca is pleased to announce that the US Food and Drug Administration (FDA) has approved a new treatment regimen for CALQUENCE® (acalabrutinib) in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
